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Abetrlct 
Postpartool depression (PPD) i& a major depressive episode fonow-
ing childbirth 1hat can ha¥e serious consequences affecting the fam-
ily. Consequences range from marital problems and issues with child 
development to maternal suicide and infantlcide. Depressiofl in moth-
ers can lead to cognitive and social impairment in the child 81 well 81 
paternal postparlum depression in the father. Due to the seYerity of 
these problems, II is important to diagnose and nat mothers as soon 
as possible. There are several s~mptoms that are e¥ident in mothers 
aufferiog from PPD that lead lo a diagnosis. Symptoms n similar to 
1t108e of IR8jor depressi¥t epi8odes, but tfley occur 24 hours to sev-
eral months poslpartum. Treatment options for PPD include psycho-
therapy as welt as tricyctic antidepressants and selective serotonin 
reuptake inhibitors. While these medications have been shown to be 
the most etfecrtve pharmacological options, more researth needs to 
be conducted to establish their effects on the infants. The possibilily 
of preventative therapy also needs to be addressed to milimize the 
long-term e1lects of the disorder. 
Introduction 
Postpartum depression (PPD) is a major depressive episode in which 
onset usually occurs within four weeks of delivery and affects ap-
proximately 13 percent of postpartum women.1•2 This disorder can be 
damaging to the mother and the rest of the family. It may result in marital 
problems as well as emotional, behavioral and interpersonal problems 
in the child subject to this situation.3 While severe postnatal depression 
is easily detected, less severe presentations can be easily dismissed as 
normal or natural consequences of childbirth. Failure to recognize post-
partum mood disturbances can possibly lead to tragic consequences for 
the mother and/or child, most notably maternal suicide and infanticide.3 
Due to these serious consequences, early diagnosis and appropriate 
intervention(s) are imperative for the health and well-being of the family. 
Symptoms and Risk Factors 
Symptoms of postpartum depression, also known as puerperal depres-
sion, are listed in Table 1. 
Table 1. Symptoms of postpartum depression1 
Depressed mood Fatigue or loss of energy 
Marked loss of interest in most Feelings of worthlessness 
activities 
Significant weight loss or gain Excessive or inappropriate guilt 
Insomnia or hypersomnia Diminished ability to think or concentrate 
Psychomotor agitation or retardation Recurrent thoughts of death 
Diagnosis requires that five of these symptoms be present during a two-
week period and that at least one of them is either depressed mood or 
marked loss of interest in virtually all activities. A woman is at a greater 
risk of developing PPD if she was depressed during pregnancy, experi-
enced anxiety or a stressful life event during pregnancy, had low levels of 
social support (including marital support), or had a history of depression.3 
Other risk factors for PPD include annual income of less than $20,000, 
less than a college education, low occupational prestige, single marital 
status and multiple offspring.5 These issues may be stressors that lead 
to increased anxiety and risk of depression. Maternity blues are another 
possible predictor of PPD.6 The blues are described by mild depressive 
symptoms, tearfulness, sorrow, unstable moods, anxiety and confusion. 
These symptoms usually peak within three to five days after birth and 
can last a couple of hours to a couple of weeks. Prevalence of maternity 
blues is estimated between 40-60 percent of postpartum women. 
Fathers also may experience postpartum depression. The number one 
risk factor for paternal postpartum depression is maternal depression.4 
Fathers are 2.5 times more likely to become depressed if they have a 
depressed partner. If both parents are depressed, this may negatively 
impact the development of their child. For men, the most important risk 
factor to note is a partner with PPD. Fathers also are at an increased risk 
if they have a history of depression or comorbidities, including obsessive-
compulsive disorder (OCD) or anxiety. Some possible biologic risk fac-
tors include low testosterone, cortisol, vasopressin, or prolactin levels or 
dysregulation of estrogen levels. PPD in fathers is also an important area 
of study because it can adversely affect the development of the child, 
similar to a mother suffering from the illness. 
Impact of PPD 
In an effort to determine the effects of PPD on an infant, researchers 
contacted mothers nine months postpartum who had reported low to high 
levels of depression two days after giving birth. 7 There were 100 women 
included in the study, 45 percent of whom were first-time mothers. To 
eliminate any other contributing factors, the study included only mothers 
in stable relationships who were healthy and educated and delivered 
a healthy full-term infant. The mothers were divided into three groups: 
those who were diagnosed with major depressive disorder at nine months 
postpartum (22 mothers), those diagnosed with an anxiety disorder at 
nine months postpartum (19 mothers), and those who were not anxious 
or depressed nine months postpartum (59 mothers). The study included 
two home visits. At the first visit, the mothers were assessed using DSM 
IV and self-report measures, while the second visit involved taping the 
mothers playing with their infants. The infants were shown increasingly 
scary masks to assess fear responses. Saliva samples also were taken 
from both the mothers and the infants to assess cortisol levels, a stress 
hormone. The infants were evaluated on essential behaviors necessary 
for social-emotional growth, including levels of sensitivity, intrusiveness, 
social engagement, withdrawal, tear regulation and cortisol reactivity. 
The infants with depressed mothers scored the lowest in all of these 
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areas. Mothers who are depressed show a decreased sensitivity toward 
their infants, which can inhibit social skills that must be learned through 
modeling. Sensitivity from the mother, shown by actions such as giving 
the child attention and time to rest, helps an infant adapt to a changing 
environment. Since the infants of depressed mothers lack this attention, 
they are more likely to have an increased fear response and cry more 
often. Infants who have not learned to regulate their fear will be more 
prone to anxiety disorders in later stages of life. 
A child is more likely to develop improperly if both parents are depressed.4 
Research shows that a child raised with unresponsive or chaotic parenting 
may have increased cortisol levels, which can hinder brain development, 
physiological growth and immune system maturity. The cognitive and 
emotional regulation in an infant can be decreased as a result of lack of 
maturation of the orbitofrontal cortex due to a poor interaction between 
a depressed parent and the infant. Paternal interaction with an infant is 
important for a child's cognitive, emotional and social development. Some 
explanations for the effects of paternal depression on a child's behavior 
include poor father-child interactions, increased marital conflict (indirect 
effects), and genetic predisposition.8 Children with depressed fathers show 
greater evidence for behavioral and conduct problems, including hyper-
activity disorders.4 This relationship seems to be greater in boys than in 
girts. Paternal depression also has been associated with low psychosocial 
functioning, leading to an elevated suicidal ideation and attempt rates in 
sons and depression in daughters. Tests show that paternal depression is 
strongly associated with increased risk of high total problem scores on the 
Rutter preschool scales and with high scores on the three problem sub-
scales (emotional, conduct and hyperactivity). These problems become 
evident in children ages 3 to 5. 
Treatment 
Treatment and recovery time for postpartum depression (PPD) var-
ies based on the severity of the depression symptoms experienced by 
the mother.9 There are a number of management options available for 
women who experience PPD, and, as with many other psychological dis-
orders, it is better to treat the conditions immediately following diagnosis. 
Postpartum depression can begin anywhere from 24 hours to several 
months after delivery and in some severe cases can last up to two 
years. Clinical evidence has shown that sex steroids, like estrogen, have 
effects on the areas responsible for mood and cognition in the central 
nervous system.10 When childbirth occurs, there is a rapid drop in estro-
gen in a woman's body that is thought to trigger depressive symptoms. 
Currently, estrogen replacement therapies are being investigated for 
possible prophylactic use in some women; however, until more informa-
tion is available on hormone-based treatments, management for PPD is 
still based on non-puerperal depression. 
The first line of therapy for a woman experiencing the signs of PPD is 
often psychotherapy.10 This is heavily due to the fact that mothers who 
breastfeed want a nonpharmacologic option to avoid exposing their 
newborn to antidepressant medications. Counseling from a trained clini-
cal psychologist or psychiatrist is often beneficial for both new mothers 
and fathers to find ways to cope with their feelings, solve problems and 
set realistic goals for parenting. The partner or the significant other also 
should be well-informed of the nature of PPD. While it is beneficial to 
support the mother, the significant other may be experiencing depres-
sion as well due to the anxiety and changing roles that parenting brings. 
Knowing that they have someone to talk to can take stress off of both 
parents and, in turn, help depression symptoms. For some, marital or 
family therapy may be beneficial as well. 
For more severe cases of PPD that are not manageable through 
psychotherapy alone, there are many antidepressant treatment options 
available through prescription. If a mother is finding it difficult to take 
care of her baby or herself, or is having thoughts of harming herself 
or the child, she should talk to her doctor to weigh the benefits along 
with the potential risks of antidepressant therapy. In most cases, the 
benefits will outweigh the risks in women with moderate to severe PPD. 
The most frequently prescribed antidepressants for both puerperal and 
non-puerperal depression have been tricyclic antidepressants, includ-
ing imipramine, desimipramine, amitriptyline and nortriptyline.11 These 
medications are thought to interfere with the reuptake of norepinephrine 
and serotonin. These four agents are all rated by the American Academy 
of Pediatrics (AAP) as drugs "of concern" and are not recommended for 
use by lactating mothers, although they are not currently contraindicated 
by the Food and Drug Administration. 12 However, the selective serotonin 
reuptake inhibitors (SSRls), such as fluoxetine, sertraline, paroxetine 
and fluvoxamine, which have a higher specificity for blocking serotonin 
reuptake, may be better tolerated and have an advantage of once-daily 
dosing.9 The SSRI chosen is an important issue for lactating mothers. In 
the case of some SSRls, such as paroxetine and sertraline, although the 
agents are excreted in the breast milk, infants are exposed to a relatively 
low dose of the drug, with serum concentrations not even detectable 
in the children. No adverse effects have been reported, and, although 
the medication is considered to be "of concern" due to the excretion of 
the drugs, it may be used if it is deemed that the benefits of treatment 
outweigh risks to the child. Other SSRls (escitalopram, citalopram) 
are excreted in the breast milk in higher quantities than sertraline or 
paroxetine, causing the infant to be potentially exposed to a greater 
amount of drug. Side effects such as excessive somnolence, decreased 
feeding and irritability have been reported in infants exposed to these 
medications through breast milk. However, the manufacturers state that 
the decision for a breast-feeding mother to use these agents should be 
based on risk to the infant versus therapeutic benefit to the mother. The 
FDA recommends that fluoxetine not be taken when breastfeeding due 
to excretion in the breast milk along with measurable serum concentra-
tions, which can be seen in the child. Colic, slow weight gain and sleep 
disorders have been associated with infants exposed to this medication. 
As a result, the drug is not recommended by the manufacturer for use in 
lactating mothers.13 
As with most antidepressant medications, patients typically show 
improvement of symptoms within two to four weeks of starting the medi-
cation.9 If no improvement has been seen during the first two weeks of 
therapy, the dose of the medication can be increased. Further increasing 
of the antidepressant should occur no sooner than seven days after the 
last dosage increase. If there is no clinical improvement in six to eight 
weeks, the mothers should be referred to a psychiatrist for a psycho-
logical evaluation. Although the duration of treatment has not been 
specifically established, a rough estimate of nine to 12 months has been 
suggested in women experiencing their first episode of PPD. 
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Conclusion 
Childbirth is a stressful situation that causes many changes in the lives 
of the new parents. This new adjustment can cause significant changes 
in the mood and behavior of the parents, which may lead to cognitive 
and social impairment in the child. Managing the disorder is important for 
the mental health of the parents and the development of their children 
both emotionally and behaviorally. Tricyclics and SSRls are currently 
the most effective pharmacologic treatments for mothers suffering from 
PPD. However, more research needs to be conducted to determine the 
effect of these medications on the infant and if prevention therapy can 
be utilized before the child is born. More studies regarding the effects of 
childbirth on men, their potential to develop PPD and possible treatment 
options should also be completed. 
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